Director Aaron Kantoff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director aaron kantoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Aaron Kantoff Today - Breaking & Trending Today

Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week High at $33.66

Tourmaline Bio (NASDAQ:TRML) Sets New 52-Week High at $33.66
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Sandeep Chidambar Kulkarni , Aaron Kantoff , Leerink Partnrs , Piper Sandler , Tourmaline Bio Inc , Securities Exchange Commission , Jefferies Financial Group , Tourmaline Bio , Get Free Report , Financial Group , Bio Trading Down , Chidambar Kulkarni , Exchange Commission , Director Aaron Kantoff , Tourmaline Bio Daily ,

Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from Analysts at Truist Financial

Truist Financial initiated coverage on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a research note issued to investors on Friday morning, MarketBeat reports. The firm issued a buy rating and a $43.00 target price on the stock. TRML has been the topic of several other reports. Piper Sandler assumed coverage on shares of […] ....

New York , United States , Piper Sandler , Caley Castelein , Aaron Kantoff , Securities Exchange Commission , Tourmaline Bio Company Profile , Tourmaline Bio Inc , Truist Financial , Tourmaline Bio , Free Report , Director Caley Castelein , Exchange Commission , Director Aaron Kantoff , Get Free Report , Thyroid Eye Disease , Tourmaline Bio Daily , Nasdaq Trml , Initiated Coverage , Truist Financial Co ,

Truist Financial Begins Coverage on Tourmaline Bio (NASDAQ:TRML)

Analysts at Truist Financial began coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a report released on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $43.00 price target on the stock. Truist Financial’s target price indicates a potential upside of 160.92% from the company’s previous close. TRML has […] ....

New York , United States , Aaron Kantoff , Sandeep Chidambar Kulkarni , Piper Sandler , Securities Exchange Commission , Tourmaline Bio Inc , Tourmaline Bio Company Profile , Truist Financial , Tourmaline Bio , Get Free Report , Chidambar Kulkarni , Exchange Commission , Director Aaron Kantoff , Thyroid Eye Disease , Tourmaline Bio Daily , Nasdaq Trml , Initiated Coverage , Truist Financial Co ,